# Scynexis Inc: overview SCYX · Nasdaq · CIK 1178253 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/scyx.md) · [Financials](/companies/scyx/financials.md) · [Filings](/companies/scyx/filings.md) · [Insiders](/companies/scyx/insiders.md) Latest reported revenue: [$235.0k](/filings/0001178253-26-000027.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001178253-26-000027). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.7](/filings/0001178253-25-000010.md) | [1.0 d](/filings/0001178253-26-000007.md) | [0.3](/filings/0001178253-26-000011.md) | [1.4](/filings/0001178253-26-000027.md) | [0.3](/filings/0001178253-25-000010.md) | [18.6 d](/filings/0001178253-26-000007.md) | [0.0](/filings/0001178253-26-000011.md) | [0.2](/filings/0001178253-26-000027.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1563.6%)](/filings/0001178253-25-000010.md) | [(824.3%) d](/filings/0001178253-26-000007.md) | [(3350.2%)](/filings/0001178253-26-000011.md) | [(701.0%)](/filings/0001178253-26-000027.md) | [(2516.5%)](/filings/0001178253-25-000010.md) | [56.4% d](/filings/0001178253-26-000007.md) | not reported | [(3308.5%)](/filings/0001178253-26-000027.md) | | Net margin | % | [(425.5%)](/filings/0001178253-25-000010.md) | [(453.7%) d](/filings/0001178253-26-000007.md) | [(2097.7%)](/filings/0001178253-26-000011.md) | [(504.8%)](/filings/0001178253-26-000027.md) | [(2572.2%)](/filings/0001178253-25-000010.md) | [65.7% d](/filings/0001178253-26-000007.md) | not reported | [3147.7%](/filings/0001178253-26-000027.md) | | Diluted EPS | $ per share | [(0.06)](/filings/0001178253-25-000010.md) | not reported | [(0.11)](/filings/0001178253-26-000011.md) | [(1.11)](/filings/0001178253-26-000027.md) | [(0.17)](/filings/0001178253-25-000010.md) | not reported | [(0.42)](/filings/0001178253-26-000011.md) | [0.63](/filings/0001178253-26-000027.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [13.2](/filings/0000950170-23-011138.md) | [5.1](/filings/0000950170-24-038046.md) | [140](/filings/0000950170-25-038044.md) | [3.7](/filings/0001178253-26-000007.md) | [20.6](/filings/0001178253-26-000007.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(462.2%)](/filings/0000950170-23-011138.md) | [(1684.5%)](/filings/0000950170-24-038046.md) | [51.9%](/filings/0000950170-25-038044.md) | [(990.8%)](/filings/0001178253-26-000007.md) | [(78.0%)](/filings/0001178253-26-000007.md) | | Net margin | % | [(249.7%)](/filings/0000950170-23-011138.md) | [(1233.7%)](/filings/0000950170-24-038046.md) | [47.8%](/filings/0000950170-25-038044.md) | [(568.3%)](/filings/0001178253-26-000007.md) | [(41.8%)](/filings/0001178253-26-000007.md) | | Diluted EPS | $ per share | [(1.25)](/filings/0000950170-23-011138.md) | [(1.47)](/filings/0000950170-24-038046.md) | [1.39](/filings/0000950170-25-038044.md) | [(0.44)](/filings/0001178253-26-000007.md) | [(0.17)](/filings/0001178253-26-000007.md) | | Free cash flow | $m | [(54.6)](/filings/0000950170-23-011138.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/scyx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GREAT POINT PARTNERS LLC](/funds/1281446.md) | 2026-06-30 | $3.8m | 944,292 | | New +944,292 | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $3.1m | 756,884 | | New +756,884 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $2.2m | 543,478 | | New +543,478 | | [Propel Bio Management, LLC](/funds/1969764.md) | 2026-06-30 | $2.2m | 543,478 | | New +543,478 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $1.6m | 387,520 | | New +387,520 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.2m | 296,747 | | New +296,747 | | [Avidity Partners Management LP](/funds/1791827.md) | 2026-06-30 | $1.1m | 260,206 | | New +260,206 | | [KINGDON CAPITAL MANAGEMENT, L.L.C.](/funds/1000097.md) | 2026-06-30 | $1.0m | 247,811 | | New +247,811 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $735.8k | 180,788 | | New +180,788 | | [HEIGHTS CAPITAL MANAGEMENT, INC](/funds/1081698.md) | 2026-06-30 | $612.7k | 150,551 | | New +150,551 | ## Recent filings [All 713 filings](/companies/scyx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 16:01 ET | [8-K](/filings/0001178253-26-000037.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001178253-26-000037 | | 2026-09-22 | 08:05 ET | [8-K](/filings/0001178253-26-000035.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001178253-26-000035 | | 2026-09-10 | 08:05 ET | [8-K](/filings/0001178253-26-000031.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001178253-26-000031 | | 2026-08-10 | 16:01 ET | [10-Q](/filings/0001178253-26-000027.md) | Quarterly report, period 2026-06-30 | 0001178253-26-000027 | | 2026-06-26 | 16:01 ET | [8-K](/filings/0001178253-26-000021.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001178253-26-000021 | | 2026-05-29 | 16:01 ET | [8-K](/filings/0001178253-26-000017.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001178253-26-000017 | | 2026-05-22 | 16:20 ET | [8-K](/filings/0001178253-26-000014.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001178253-26-000014 | | 2026-05-11 | 16:01 ET | [10-Q](/filings/0001178253-26-000011.md) | Quarterly report, period 2026-03-31 | 0001178253-26-000011 | | 2026-04-30 | 16:29 ET | [DEF 14A](/filings/0001140361-26-018207.md) | Proxy statement, period 2026-06-25 | 0001140361-26-018207 | | 2026-04-27 | 16:18 ET | [DEF 14A](/filings/0001140361-26-017112.md) | Proxy statement, period 2026-05-19 | 0001140361-26-017112 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001178253-26-000007.md), filed Mar 4, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3a158d6d-7e88-4886-94c1-82fb0d05a08b) ## About the filer - CIK: 1178253 - Tickers: SCYX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.